ABSTRACT
Objective To evaluate the clinical significance of the clinical diagnosis and efficacy monitoring of serum gastrin-releasing peptide precursor (ProGRP) in small cell lung cancer (SCLC) patients.Methods A total of 4032 patients were admitted to a hospital from March 2015 to August 2017, determining serum ProGRP concentrations of 144 patients with small cell lung cancer, 1618 patients with the non-small cell lung tumor group, 42 patients with benign lung tumors, 231 with extrapulmonary malignant tumors, 275 with extrapulmonary benign disease, 1, 402 with benign lung disease, and 320 healthy patients.Analysis and evaluation of ProGRP values before and after treatment in patients with SCLC changes and the correlation of tumor size.Results Serum ProGRP levels in small cell lung cancer group were higher than those in each group.U test shows P＜0.05 in each group.U test shows P＜0.05 in patients with renal failure and healthy controls;prolonged ProGRP values in patients with small cell lung cancer were higher than the limited period.U test shows P＜0.05.Serum ProGRP U-test shows P＜0.05 between before and after treatment in small cell lung cancer progression and remission groups.Serum ProGRP U-test shows P＞0.05 between before and after treatment in small cell lung cancer stable group.Serum ProGRP concentration and tumor mass in small cell lung cancer The size is consistent.Compared with healthy control group, the lung non-small cell tumor group, lung benign tumor group, extrapulmonary malignant tumor group, intrapulmonary benign disease group conduct U test, showing P＞0.05.Conclusion Serum ProGRP is a specific tumor marker of SCLC without the interference of renal failure.It can be used as an auxiliary basis for SCLC staging, monitoring prognosis, and evaluating clinical efficacy of important indicators.
ABSTRACT
Objective To observe the significance of tumor abnormal protein (TAP)in the therapeutic monitoring of non-small cell lung cancer (NSCLC).Methods Peripheral blood from 30 NSCLC patients were collected to make smears at the moment of pre-treatment,half a month,one month,3 months and 6 months after therapy.TAP was detected by coacervation method.The maximum area of condense was applied to estimate the level of TAP.Thirty healthy subj ects were chose as con-trol group.Results The positive rate of TAP in NSCLC patients was 86.67%,and 3.33% of healthy subjects were positive in TAP.The difference was statistically significant (χ2=140.3,P<0.01).The condense area of TAP in patients withⅢ~Ⅳ stage of NSCLC [411(89,562)mm2]was significantly higher than those withⅠ~Ⅱ stage NSCLC [267(31,407)mm2]. The condense areas in both of two groups went down after treatment.A significant difference of condense area appeared inⅠ~Ⅱ stage of NSCLC patients a month after therapy as well as Ⅲ~Ⅳ stage of NSCLC patients half a month after treat-ment.The condense areas went to their lowest level 3 months after therapy.ForⅠ~Ⅱ stage patients,the condense area fell to 21% compared to that before treatment,but for patients withⅢ~Ⅳ stage of NSCLC,37% of pre-treatment condense ar-ea were detected.TheⅠ~Ⅱ stage of NSCLC patients had a greater decrease in condense area of TAP than theⅢ~Ⅳ stage patients by 3 months after treatment (χ2=6.22,P<0.05).Conclusion Detection of TAP in peripheral blood had a high sensitivity for NSCLC,and is able to monitoring the treatment effect.
ABSTRACT
The authors report a case where a quantitative assessment of the apparent diffusion coefficient (ADC) of liver metastasis in a patient undergoing chemotherapy has shown to be an effective early marker for predicting therapeutic response, anticipating changes in tumor size. A lesion with lower initial ADC value and early increase in such value in the course of the treatment tends to present a better therapeutic response.
Relatamos um caso no qual a avaliação quantitativa do coeficiente de difusão aparente (ADC) de metástases hepáticas submetidas a quimioterapia se mostrou um bom preditor e marcador precoce de resposta terapêutica, antecipando alterações de tamanho. Lesão com valor inicial do ADC mais baixo e com aumento precoce deste valor no curso do tratamento tende a apresentar melhor resposta terapêutica tardia.